Clinical outcomes and treatment practice patterns of patients with HER2-positive metastatic breast cancer in the post-trastuzumab era.

Abstract

BACKGROUND Trastuzumab is associated with improvements in overall survival (OS) among patients with HER2-positive metastatic breast cancer (MBC); however disease course and patterns of care in individual patients are highly variable. METHODS 113 HER2-positive patients diagnosed with MBC from 1999 to 2005 who received trastuzumab-based therapy were… (More)
DOI: 10.1016/j.breast.2012.12.006

Topics

Cite this paper

@article{Olson2013ClinicalOA, title={Clinical outcomes and treatment practice patterns of patients with HER2-positive metastatic breast cancer in the post-trastuzumab era.}, author={Erin M. Olson and Julie S Najita and Jessica Sohl and Amal Arnaout and Harold J. Burstein and Eric P. Winer and Nancy U. Lin}, journal={Breast}, year={2013}, volume={22 4}, pages={525-31} }